On August 20, 2019, the SEC charged a pharmaceutical company with violations of Regulation FD based on its sharing of material, nonpublic information with sell-side research analysts on two separate occasions without also disclosing the same information to the public.

The SEC found that on two separate occasions in June 2017, the company selectively disclosed